Pennant Group Inc (PNTG) valuation
Pennant Group P/E ratio history
Pennant Group trades at 45.8 times its earnings over the last twelve months and 27.9 times the earnings analysts expect over the next twelve. At its last 7 fiscal year ends its P/E ranged from 31.6 (year to Dec 2023) to 300.6 (year to Dec 2019), with a median of 49.9.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $28.15 | $0.84 | 33.5 | 22.0 |
| Dec 31, 2024 | $26.52 | $0.70 | 37.9 | 25.2 |
| Dec 31, 2023 | $13.92 | $0.44 | 31.6 | 17.1 |
| Dec 31, 2022 | $10.98 | $0.22 | 49.9 | — |
| Dec 31, 2021 | $23.08 | $0.09 | 256.4 | 32.4 |
| Dec 31, 2020 | $58.06 | $0.52 | 111.7 | — |
| Dec 31, 2019 | $33.07 | $0.11 | 300.6 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Pennant Group valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Pennant GroupPNTG | $1.45B | 45.8 | 27.9 | 1.3 |
| Pacira BiosciencesPCRX | $1.43B | 101.1 | 11.5 | 1.9 |
| Eton PharmaceutcialsETON | $1.43B | 133.8 | 26.4 | 13.5 |
| Agilon HealthAGL | $1.42B | — | 77.3 | 0.2 |
| AnaptysbioANAB | $1.41B | — | 10.8 | 5.9 |
| Mineralys TherapeuticsMLYS | $1.50B | — | — | — |
| Alignment HealthcareALHC | $1.51B | 36.4 | 13.8 | 0.3 |
| Nutex HealthNUTX | $1.38B | 7.7 | 7.3 | 1.6 |
| Ocular TherapeutixOCUL | $1.53B | — | — | 29.3 |
| Peer median | 68.7 | 12.6 | 1.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PNTG financials · PNTG returns
No forecast, no recommendation. This page describes Pennant Group Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.